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THE METABOLIC SYNDROME CON-sists of a constellation of fac-tors that increase the risk ofcardiovascular disease and type
2 diabetes. Recent estimates indicate
that the metabolic syndrome is highly
prevalent in the United States, with an
estimated 24% of the adult population
affected.1 Its clinical identification is
based on measures of abdominal obe-
sity, atherogenic dyslipidemia, el-
evated blood pressure, and glucose
intolerance.2 The etiology of this syn-
drome is largely unknown but presum-
ably represents a complex interaction
between genetic, metabolic, and envi-
ronmental factors including diet.3,4 Sev-
eral recent studies also suggest that a
proinflammatory state is one compo-
nent of the metabolic syndrome.5-8
Moreover, evidence has accumulated
indicating that low-grade inflamma-
tion is associated with endothelial dys-
function.9,10
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Context The metabolic syndrome has been identified as a target for dietary thera-
pies to reduce risk of cardiovascular disease; however, the role of diet in the etiology
of the metabolic syndrome is poorly understood.
Objective To assess the effect of a Mediterranean-style diet on endothelial func-
tion and vascular inflammatory markers in patients with the metabolic syndrome.
Design, Setting, and Patients Randomized, single-blind trial conducted from
June 2001 to January 2004 at a university hospital in Italy among 180 patients (99
men and 81 women) with the metabolic syndrome, as defined by the Adult Treat-
ment Panel III.
Interventions Patients in the intervention group (n=90) were instructed to follow
a Mediterranean-style diet and received detailed advice about how to increase daily
consumption of whole grains, fruits, vegetables, nuts, and olive oil; patients in the con-
trol group (n=90) followed a prudent diet (carbohydrates, 50%-60%; proteins, 15%-
20%; total fat, 30%).
Main Outcome Measures Nutrient intake; endothelial function score as a mea-
sure of blood pressure and platelet aggregation response to L-arginine; lipid and glu-
cose parameters; insulin sensitivity; and circulating levels of high-sensitivity C-
reactive protein (hs-CRP) and interleukins 6 (IL-6), 7 (IL-7), and 18 (IL-18).
Results After 2 years, patients following the Mediterranean-style diet consumed more
foods rich in monounsaturated fat, polyunsaturated fat, and fiber and had a lower ra-
tio of omega-6 to omega-3 fatty acids. Total fruit, vegetable, and nuts intake (274
g/d), whole grain intake (103 g/d), and olive oil consumption (8 g/d) were also sig-
nificantly higher in the intervention group (P.001). The level of physical activity in-
creased in both groups by approximately 60%, without difference between groups
(P=.22). Mean (SD) body weight decreased more in patients in the intervention group
(−4.0 [1.1] kg) than in those in the control group (−1.2 [0.6] kg) (P.001). Com-
pared with patients consuming the control diet, patients consuming the intervention
diet had significantly reduced serum concentrations of hs-CRP (P=.01), IL-6 (P=.04),
IL-7 (P=0.4), and IL-18 (P=0.3), as well as decreased insulin resistance (P.001). En-
dothelial function score improved in the intervention group (mean [SD] change, +1.9
[0.6]; P.001) but remained stable in the control group (+0.2 [0.2]; P=.33). At 2 years
of follow-up, 40 patients in the intervention group still had features of the metabolic
syndrome, compared with 78 patients in the control group (P.001).
Conclusion A Mediterranean-style diet might be effective in reducing the preva-
lence of the metabolic syndrome and its associated cardiovascular risk.
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Although aspects of diet have been
linked to individual features of the
metabolic syndrome,11 the role of diet
in the etiology of the syndrome is poorly
understood and limited to only a few
observational studies.12,13 The Adult
Treatment Panel III recommenda-
tions for patients with the metabolic
syndrome are consistent with general
dietary recommendations.14 Recently,
the scientific advisory committee of the
American Heart Association has stated
that a Mediterranean-style diet has im-
pressive effects on the progression of
cardiovascular disease.15
The aim of this study was to assess
the effect of a Mediterranean-style diet
on endothelial function and vascular
inflammation in patients with the
metabolic syndrome. We studied
endothelial function by assessing the
vascular responses to L-arginine, the
natural precursor of nitric oxide.
Moreover, we characterized the low-
grade inflammatory state of patients
with the metabolic syndrome by mea-
suring circulating levels of high-
sensitivity C-reactive protein (hs-
CRP) as well as of interleukins 6
(IL-6), 7 (IL-7), and 18 (IL-18). These
proinflammatory ILs have been pro-
spectively associated with thrombotic
cardiovascular events16,17 or have been
suggested to be involved in plaque
destabilization.18 We then performed
a randomized controlled trial of a
Mediterranean-style diet designed to
increase consumption of foods rich
in phytochemicals, antioxidants,
-linolenic acid, and fiber.
METHODS
Men and women were recruited from
June 2001 to January 2004 among those
attending the outpatient department of
the Division of Metabolic Diseases at the
Second University of Naples, Naples,
Italy. The study participants were sed-
entary (engaging in less than 1 hour per
week of physical activity) and within
the previous 6 months had no evi-
dence of participation in weight reduc-
tion programs and had maintained a
stable weight (±1 kg). None of the study
participants had previously partici-
pated in dietary studies. Each patient
was asked to complete a personal health
and medical history questionnaire that
served as a screening tool.
To be enrolled in the study, patients
had to have 3 or more of the following
criteria to meet the diagnosis of the meta-
bolic syndrome, as defined by the Adult
Treatment Panel III2: (1) abdominal adi-
posity (defined as waist circumference
102 cm [men] or 88 cm [wom-
en]); (2) low levels of serum high-
density lipoprotein cholesterol (40
mg/dL [men] or 50 mg/dL [wom-
en]); (3) hypertriglyceridemia (triglyc-
erides level of 150 mg/dL or greater); (4)
elevated blood pressure (130/85 mm Hg
or greater); and (5) impaired glucose
homeostasis (fasting plasma glucose
concentration of 110 mg/dL or greater).
Patients were excluded if they had car-
diovascular disease, psychiatric prob-
lems, a history of alcohol abuse (alco-
hol consumption500 g/wk in the last
year), if they smoked, or if they took any
medication. The study was approved by
the institutional committee of ethical
practice of the Second University of
Naples, and all of the study patients gave
written informed consent.
Patients were randomly assigned to
either the intervention or the control diet
using a computer-generated random
number sequence (FIGURE 1). Alloca-
tion was concealed in sealed study fold-
ers that were held in a central, secured
location until after informed consent was
obtained. The nurses who scheduled the
study visits did not have access to the
randomization list. However, the staff
members involved in the intervention
had to be aware of the group assign-
ment; thus, the study was only partly
blinded. Laboratory staff did not know
the patients’ group assignments.
Patients consuming the interven-
tion diet were given detailed advice
about the usefulness of the experimen-
tal diet. Through a series of monthly
small-group sessions, intervention pa-
tients received education in reducing
dietary calories (if needed), personal
goal-setting, and self-monitoring us-
ing food diaries. Behavioral and psy-
chological counseling was also of-
fered. The dietary advice was tailored
to each patient on the basis of 3-day
food records. The recommended com-
position of the dietary regimen was as
follows: carbohydrates, 50% to 60%;
proteins, 15% to 20%; total fat, less than
30%; saturated fat, less than 10%; and
cholesterol consumption, less than 300
mg per day. Moreover, patients were ad-
vised to consume at least 250 to 300 g
of fruits, 125 to 150 g of vegetables, and
25 to 50 g of walnuts per day; in addi-
tion, they were also encouraged to con-
sume 400 g of whole grains (legumes,
rice, maize, and wheat) daily and to in-
crease their consumption of olive oil.
Patients were in the program for 24
months and had monthly sessions with
the nutritionist for the first year and bi-
monthly sessions for the second year.
Compliance with the program was as-
sessed by attendance at the meetings
and completion of the diet diaries.
Patients consuming the control diet
were given general oral and written in-
formation about healthy food choices
at baseline and at subsequent visits but
were offered no specific individual-
ized program. However, the general rec-
ommendation for macronutrient com-
position of the diet was similar to that
for the intervention group (carbohy-
drates, 50%-60%; proteins, 15%-20%;
and total fat, 30%). Moreover, pa-
tients in the control group also had bi-
monthly sessions with study person-
nel during the 2-year study. All patients
in both groups also received guidance
Figure 1. Flow of Patients Through the Trial
220 Patients Assessed for Eligibility
90 Included in Analysis 90 Included in Analysis
90 Assigned to Receive a
Mediterranean-Style Diet
90 Assigned to Receive a
Control Prudent Diet
180 Randomized
40 Ineligible
20 Did Not Meet
Protocol Criteria
20 Unwilling to
Participate
8 Dropped Out
(Declined
Follow-up)
8 Dropped Out
(Declined
Follow-up)
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on increasing their level of physical ac-
tivity, mainly by walking for a mini-
mum of 30 minutes per day but also by
swimming or playing aerobic ball games
(eg, soccer).
Height and weight were recorded
with participants wearing lightweight
clothing and no shoes using a Seca 200
scale with attached stadiometer (Seca,
Hamburg, Germany). Twenty-four–
hour nutrient intakes were calculated
with food-composition tables and pa-
tients’ weekly diet diaries. To assess di-
etary adherence and exercise activity,
all patients were asked to complete a
3-day food record and to record occu-
pational,1 household, and leisure-
time physical activity. Foods were mea-
sured using standard measuring cups
and spoons and weight-approxima-
tion diagrams.
Endothelial Function
Endothelial function was assessed with
the L-arginine test, as previously
described.19,20 Briefly, after applying a
device for automatic measurements of
blood pressure and heart rate (Omheda
2300; Finapres, Englewood, Calif), an
intravenous bolus of 3 g of L-arginine
(10 mL of a 30% solution of L-arginine
monochloride), the natural precursor
of nitric oxide, was injected intrave-
nously within 60 seconds. Blood
pressure and platelet aggregation
response to 1.25 µM adenosine diphos-
phate were measured before L-argi-
nine injection and after 10 minutes.
We developed a score in which both
responsesweresummed.Forbloodpres-
sure, 1 point was attributed for a mean
blood pressure response less than 2
mm Hg, 2 points for a response between
2 and 3 mm Hg, 3 points for a response
between 3 and 4 mm Hg, 4 points for a
response between 4 and 5 mm Hg, and
5 points for a response greater than 5
mm Hg. For platelet aggregation, 1 point
was attributed for a response less than
2.5%, 2 points for a response between
2.5% and 5%, 3 points for a response
between 5% and 7.5%, 4 points for a
response between 7.5% and 10%, and 5
points for a response greater than 10%.
In our laboratory, the mean (SD) blood
pressure and platelet aggregation
decreases following the L-arginine bolus
(differencebetweenbasal and10-minute
values) in a matched control group of
healthymenandwomen(n=50foreach)
were −6.5 (1.5) mm Hg and −13% (3%),
respectively, which correspond to the
maximal score of 10.
Laboratory Analysis
Estimation of insulin sensitivity in the
fasting state was assessed with homeo-
stasis model assessment (HOMA) and
calculated with the formula: fasting
plasma glucose (mmol/L) fasting se-
rum insulin (µU/mL) divided by 25, as
described by Matthews et al.21 With
such a method, high HOMA scores de-
note low insulin sensitivity (insulin re-
sistance). Assays for serum levels of
total cholesterol and high-density li-
poprotein cholesterol, triglycerides, and
glucose were performed in the hospi-
tal’s chemistry laboratory. Plasma in-
sulin levels were assayed by radioim-
munoassay (Ares, Serono, Italy).
Serum samples for cytokine and
hs-CRP levels were stored at –80°C until
assay.Serumconcentrationsof IL-6, IL-7,
and IL-18 were determined in duplicate
using a high-sensitivity, quantitative
sandwichenzymeassay(QuantikineHS,
R&D Systems, Minneapolis, Minn).
High-sensitivity CRP was assayed by
immunonephelometry using a Behring
Nephelometer 2 (Dade Behring, Mar-
burg, Germany). In our laboratory, the
median(interquartilerange)fortheseval-
ues in a group of 100 healthy partici-
pantsofbothsexes (n=50 foreach)were
as follows: hs-CRP, 0.7 mg/L (0.2-3.2
mg/L); IL-6, 2.1 pg/mL (0.3-5.2 pg/mL);
IL-7, 1.8 pg/mL (0.5-5.2 pg/mL); and
IL-18, 129 pg/mL (50-275 pg/mL).
Statistical Analysis
Data are presented as mean (SD) unless
stated otherwise. Data were analyzed by
intention-to-treat. We compared base-
linedatausinga t test for continuousvari-
ables and a Wilcoxon test for hs-CRP,
IL-6, IL-7, and IL-18. We classified all
study patients as having 3, 4, or 5 com-
ponents of the metabolic syndrome and
assessed for evidence of a relation of me-
dian hs-CRP level and mean HOMA and
endothelial function scores across these
groups using the Jonckheere-Terpstra
test. We compared risk factors and nu-
trient intakes after 2 years using a test
based on the values at the end of fol-
low-up and a t test based on differences
from baseline. Results of the analysis
omittingpatients lost in the follow-updid
not differ from that including their last
available records; data are therefore
shown for the analysis that includes all
participants as randomized. Spearman
rank correlation coefficients were used
to quantify the relations between meta-
bolic variables and cytokine levels. The
effects of treatment on HOMA and en-
dothelial function scores, cytokine lev-
els, and each of the components of the
metabolic syndrome were tested by
means of paired t tests and a Wilcoxon
matched test, after adjustment for
changes in body weight. The 2 test was
used for comparing proportions of par-
ticipants in the 2 groups with the meta-
bolic syndrome after treatment. P.05
was considered statistically significant.
All analysis were conducted using SPSS
version 9.0 (SPSS Inc, Chicago, Ill).
RESULTS
One hundred eighty patients were ran-
domly assigned to the intervention
(n=90) or control (n=90) group (Fig-
ure 1). Both groups were comparable,
including the number of components of
the metabolic syndrome (TABLE 1).
There was an increase in hs-CRP levels
and HOMA scores as the number of
components of the metabolic syn-
drome increased; by contrast, there was
an inverse relation between the num-
ber of components of the metabolic syn-
drome and the endothelial function
score (P.001 for trend for all)
(FIGURE 2). Spearman rank correlation
coefficients showed that endothelial
function score was negatively associ-
ated with waist circumference (r=−0.30,
P=.01), hs-CRP level (r=−0.33,P=.01),
HOMA score (r=−0.24,P=.02), and IL-6
level (r=−0.21, P=.02).
After 2 years of follow-up, 8 partici-
pants in the intervention group and 8
in the control group dropped out of the
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study; all dropouts occurred after 24
weeks of follow-up. Patients who
dropped out from the intervention
group showed a decrease in body
weight after 24 weeks of follow-up, sug-
gesting that they were adhering to the
lifestyle changes.
Baseline data showed no important
difference in the nutrient intake be-
tween the 2 groups (TABLE 2). After 2
years, patients following the interven-
tion diet consumed a greater percent-
age of calories from complex carbohy-
drates and from polyunsaturated and
monounsaturated fat; had a greater in-
take of fiber; had a lower ratio of
omega-6 to omega-3 fatty acids; and had
lower energy, levels of saturated fat, and
levels of cholesterol than did controls.
Total fruit, vegetable, nuts, and whole
grain intakes and olive oil consump-
tion were also significantly higher in the
intervention group (Table 2). The level
of physical activity increased in both
groups (intervention group: from 48
[SD, 10] min/wk to 84 [SD, 36] min/
wk, P.001; control group: from 51
[SD, 9] min/wk to 81 [SD, 38] min/
wk, P.001) without any difference be-
tween them (P=.22).
After 2 years, patients in the inter-
vention group had significant de-
creases in body weight; body mass in-
dex; waist circumference; HOMA score;
blood pressure; and levels of glucose, in-
sulin, total cholesterol, and triglycer-
ides and a significant increase in levels
of high-density lipoprotein choles-
terol, all of which were greater than those
recorded in the control group (TABLE3).
There was no difference for sex. Serum
concentrations of IL-6, IL-7, IL-18, and
hs-CRP were significantly reduced in pa-
tients in the intervention group com-
pared with those in the control group.
Endothelial function score improved in
the intervention group but remained
stable in the control group. There was
an inverse relation between changes in
endothelial function score and changes
in hs-CRP levels (r=−0.36, P=.01) and
HOMA scores (r=−31, P=.01).
At 2 years of follow-up, 60 partici-
pants in the intervention group had ex-
perienced reductions in the number of
components of the metabolic syn-
drome (Table 3), so that only 40 pa-
tients could still be classified as hav-
ing the metabolic syndrome. This was
significantly different from the con-
trol group, in which 78 patients were
still classified as having the metabolic
syndrome (P.001). The data unad-
Figure 2. Distribution of HOMA Score, Endothelial Function Score, and hs-CRP Levels
Among the 180 Patients at Baseline, by Presence of 3, 4, and 5 Components of the Metabolic
Syndrome
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HOMA indicates homeostasis model assessment; hs-CRP, high-sensitivity C-reactive protein. Error bars in 2
left panels indicate standard deviation; horizontal lines in boxes in right panel, median; boxes, interquartile
range.
Table 1. Characteristics of the Study Participants
Characteristics
Mean (SD)
P
Value
Intervention Diet
(n = 90)
Control Diet
(n = 90)
Sex, No. (%)
Men 49 (54) 50 (56) .70
Age, y 44.3 (6.4) 43.5 (5.9) .56
No. of components of the metabolic syndrome,
No. (%)
3 74 (82) 76 (84)
4 18 (20) 16 (18) .34
5 8 (9) 8 (9)
Body weight, kg 78 (8) 77 (8) .36
Body mass index* 27.9 (3.4) 28.1 (3.2) .55
Waist circumference, cm 92 (9) 93 (10) .62
Plasma glucose, mg/dL 113 (10) 114 (10) .43
Serum insulin, µU/mL 15 (6) 16 (7) .15
HOMA score 3.7 (0.7) 3.8 (0.7) .18
Serum lipids, mg/dL
Total cholesterol 199 (34) 193 (32) .18
HDL-C 41 (9) 42 (9) .35
Triglycerides 168 (57) 172 (54) .24
Blood pressure, mm Hg
Systolic 134 (9) 136 (10) .11
Diastolic 85 (6) 86 (7) .21
Endothelial function score 6.0 (1.2) 5.9 (1.1) .13
hs-CRP and cytokines, median (IQR)
hs-CRP, mg/L 2.8 (0.7-5.4) 2.9 (0.5-5.7) .25
IL-6, pg/mL 2.1 (0.5-4.8) 1.9 (0.5-4.7) .14
IL-7, pg/mL 2.4 (0.6-5.9) 2.6 (0.7-6.0) .12
IL-18, pg/mL 167 (102-232) 175 (104-238) .10
Abbreviations: HDL-C, high-density lipoprotein cholesterol; HOMA, homeostatic model assessment; hs-CRP, high-
sensitivity C-reactive protein; IL, interleukin; IQR, interquartile range.
SI conversion factors: To convert glucose to mmol/L, multiply values by 0.0555; to convert insulin to pmol/L, multiply
values by 7.715; to convert total cholesterol and HDL-C to mmol/L, multiply values by 0.0259; to convert triglycer-
ides to mmol/L, multiply values by 0.0113.
*Calculated as weight in kilograms divided by the square of height in meters.
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justed for changes in body weight
showed a greater reduction in the num-
ber of components of the metabolic syn-
drome, such that at 2 years of follow-
up, 30 patients in the intervention
group and 73 patients in the control
group were classified as having the
metabolic syndrome (P.001).
COMMENT
In this study, consumption of a
Mediterranean-style diet by patients
with the metabolic syndrome was asso-
ciated with improvement of endothe-
lial function and a significant reduc-
tion of markers of systemic vascular
inflammation. Moreover, participants
who followed the intervention diet
showed a reduction in the number of
the components of the syndrome such
that the overall prevalence of the meta-
bolic syndrome was reduced by
approximately one half. Because data
were adjusted for changes in body
weight, the overall reduction in the
prevalence of the metabolic syndrome
after the intervention is likely to repre-
sent a conservative measure. Taken
together, these findings suggest that a
Mediterranean-style diet is a safe strat-
egy for treatment of the metabolic syn-
drome and for helping to reduce the
associated cardiovascular risk.
Current guidelines on the manage-
ment of the individual components of the
metabolic syndrome emphasize that life-
stylemodification(weight loss andphysi-
cal activity) is a first-line therapy,whereas
drug therapy is considered secondary,
unless otherwise indicated by current
cardiovascular disease prevention guide-
lines.22 In our study, the effect of the in-
tervention diet was associated with mod-
est changes in body weight, which has
been shown to have no effect on CRP lev-
els,23 as well as an increment in physi-
cal activity not different from the con-
trol group. Because the results were
adjusted for body weight changes, our
findings suggest that, largely indepen-
dent of concomitant changes in body
weight, a Mediterranean-style diet might
play a role in reducing the inflamma-
tory state and endothelial dysfunction as-
sociated with the metabolic syndrome.
The mechanism by which a Mediter-
ranean-style diet can reduce the low-
grade inflammatorystateassociatedwith
the metabolic syndrome is unclear.
Macronutrient intake produces oxida-
tive stress that leads to a proinflamma-
tory state.24 This intriguing evidence is
also supported by the ability of antioxi-
dant vitamins25,26 or food antioxi-
dants20 to improve the transient endo-
thelial dysfunction seen in healthy
individuals after consumptionof a single
high-fat meal. Moreover, modulation of
the fiber content of the meal may influ-
ence the cytokine milieu: increasing the
fiber content (from 4.5 g to 16.8 g) of a
high-carbohydrate meal was associated
with significant reduction of circulat-
ing IL-18 levels in both healthy persons
and in patients with type 2 diabetes.27
Because dietary fiber may have anti-
inflammatory roles, at least in intesti-
nal functions,28 it can be speculated that
the fiber content of the intervention diet,
eventuallymagnifiedbysomeothercom-
ponentswithantioxidantcapability,may
influence the transient oxidative stress
that occurs after macronutrient inges-
tion. An anti-inflammatory effect for
omega-3 fatty acids also has been sug-
gested,29 although most of this effect was
seen with supplement use.
Our results show a linear increment
in hs-CRP levels and a linear impair-
ment of endothelial function score as-
sociated with increase in the number of
components of the metabolic syn-
drome. This leads to the speculation that
Table 2. Nutrient Indices at Entry to Study and After 2 Years
Nutrient
Intervention Diet (n = 90) Control Diet (n = 90) Between-Group Comparison
of Change
Mean (SD)
Mean
Change
P
Value
Mean (SD)
Mean
Change
P
Value Difference (95% CI)
P Value
at 2 YearsBaseline 2 Years Baseline 2 Years
Total energy, kcal/d 2235 (188) 2065 (168) −170 .001 2254 (198) 2184 (174) −70 .001 −100 (−178 to −21) .001
Carbohydrates, % 57.3 (2.1) 58.0 (2.0) +0.7 .02 57.0 (2.2) 57.1 (2.3) +0.1 .10 +0.6 (0.1 to 1.1) .02
Complex carbohydrates, % 44 (2.0) 50 (2.1) +6 .001 43 (2.0) 42 (2.2) −1 .06 +7 (4 to 12) .001
Fiber, g/d 14 (1.2) 32 (2.8) +18 .001 15 (1.3) 17 (1.5) +2 .02 +16 (4 to 30) .001
Protein, % 13.7 (1.3) 14.0 (1.4) +0.3 .06 13.4 (1.4) 13.5 (1.3) +0.1 .09 +0.2 (−0.1 to 0.4) .07
Fat, % 29.0 (2.8) 28.0 (2.7) −1 .01 29.6 (2.9) 30.0 (2.8) +0.4 .04 −1.4 (−2.8 to −0.2) .02
Saturated 13.0 (2.8) 8.0 (1.1) −5 .001 13.4 (2.7) 13.7 (2.6) +0.3 .06 −5.3 (−9.5 to −2.0) .001
MUFA 9.0 (1.2) 12.4 (1.7) +3.4 .001 9.2 (1.1) 9.6 (1.2) +0.4 .05 +3 (1.0 to 5.0) .001
PUFA 7.0 (0.9) 7.6 (0.9) +0.6 .001 7.0 (1.1) 6.7 (0.9) −0.3 .06 +0.9 (0.3 to 1.5) .01
Omega-3 fatty acids, g/d 0.6 (0.15) 1.5 (0.3) +0.9 .001 0.61 (0.17) 0.68 (0.2) +0.07 .10 +0.86 (0.25 to 1.4) .001
Omega-6/omega-3 fatty
acid ratio
11.2 (2.1) 6.7 (1.1) −4.5 .001 11.4 (2.1) 11.2 (1.9) −0.2 .08 −4.3 (−8.3 to −1) .001
Cholesterol, mg/d 325 (39) 236 (29) −89 .001 316 (40) 307 (31) −9 .09 −80 (−135 to −25) .001
Olive oil, g/d 15.0 (2.4) 26.7 (3.5) +9.7 .001 14.4 (2.7) 15.9 (2.9) +1.5 .02 +8.2 (3.3 to 12.4) .001
Fruits, vegetables, nuts,
and legumes, g/d
198 (20) 487 (89) +289 .001 186 (23) 201 (35) +15 .01 +274 (176 to 372) .001
Whole grains, g/d 87 (17) 198 (46) +111 .001 94 (20) 102 (26) +8 .02 +103 (45 to 159) .001
Alcohol, g/d 39 (7) 38 (10) −1 .12 37 (8) 38 (8) +1 .13 −2 (−5.6 to 1.6) .10
Abbreviations: CI, confidence interval; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids.
MEDITERRANEAN DIET AND THE METABOLIC SYNDROME
1444 JAMA, September 22/29, 2004—Vol 292, No. 12 (Reprinted) ©2004 American Medical Association. All rights reserved.
 at Seconda Universita Studi Napol on 10 December 2010jama.ama-assn.orgDownloaded from 
CRP, which is produced by the liver un-
der the influence of IL-6,9 may be one
link between the altered cytokine mi-
lieu and endothelial dysfunction associ-
ated with the metabolic syndrome. In ad-
dition to being a powerful risk marker,
recent evidence suggests that CRP may
directly participate in lesion formation
through leukocyte activation and endo-
thelial dysfunction.30,31 Moreover, it has
been suggested that increased inflam-
matory responses could lead to insulin
resistance and compensatory hyperin-
sulinemia attributable in large part to the
important role of inflammatory cyto-
kines released from adipocytes.9 Alter-
natively, insulin resistance may be re-
sponsible for the higher production of
cytokines as a consequence of reduced
anti-inflammatory effect of insulin in in-
sulin-resistant states.32 Regardless of
the mechanisms, the proinflammatory
state that accompanies the metabolic
syndrome is associated with both insu-
lin resistance and endothelial dysfunc-
tion, providing a connection between
inflammation and metabolic processes
that are highly deleterious for vascular
function.
One limitation of our study is the
inability to determine whether indi-
vidual components of the diet can
account for the changes observed or
whether the changes in metabolic risk
factors are a result of the sum of all the
dietary changes. Although multiple
dietary interventions, as in the study
herein, render difficult the assessment of
the effect of each intervention sepa-
rately, the clinical usefulness of a whole-
diet approach in the prevention of
cardiovascular disease has been empha-
sized.33 The Lyon Heart Study34 has
shown that diet can help reduce the risk
of fatalandnonfatalcardiovascularevents
in individuals with cardiovascular dis-
ease. Singh et al35 tested an Indo-
Mediterraneandiet in1000patientswith
existing coronary disease or at high risk
for coronary disease. As compared with
the control diet, the intervention diet
reduced the rate of fatal myocardial
infarction by one third and the rate of
suddendeath fromcardiaccausesby two
Table 3. Changes in Assessed Variables After 2 Years
Variable
Intervention Diet (n = 90) Control Diet (n = 90) Between-Group Comparison
of Change
Mean (SD)
P
Value
Mean (SD)
P
Value
Difference
(95% CI)
P Value
at 2 Years2 Years Change 2 Years Change
Weight, kg 74 (7) −4 (1.1) .001 75.8 (7) −1.2 (0.6) .02 −2.8 (−5.1 to −0.5) .001
Body mass index* 26.7 (3.1) −1.2 (0.3) .001 27.7 (3.1) −0.4 (0.4) .06 −0.8 (−1.4 to −0.2) .01
Waist circumference, cm 90 (8) −2 (0.5) .01 93 (10) 0 (0.01) .74 −2 (−3.5 to −0.5) .01
Plasma glucose, mg/dL 105 (9) −8 (3) .001 112 (9) −2.0 (1.5) .21 −6 (−11 to −2) .001
Serum insulin, µU/mL 11 (5) −4 (1.9) .01 15.5 (7) −0.5 (1.0) .45 −3.5 (−6.1 to −1.7) .01
HOMA score 2.5 (0.6) −1.2 (0.5) .001 3.7 (0.7) −0.1 (0.2) .12 −1.1 (−1.9 to −0.3) .001
Serum lipids, mg/dL
Total cholesterol 188 (29) −11 (6) .01 191 (30) −2 (2) .23 −9 (−17 to −1) .02
HDL-C 45 (10) +4 (2) .01 43 (9) +1 (1) .08 +3 (0.8 to 5.2) .03
Triglycerides 150 (49) −18 (8) .01 173 (53) +1 (3) .15 −19 (−32 to −6) .001
Blood pressure, mm Hg
Systolic 130 (8) −4 (2) .001 135 (10) −1 (1) .06 −3 (−5 to −1) .01
Diastolic 82 (5) −3 (1) .001 85 (6) −1 (1) .05 −2 (−3.5 to −0.5) .03
Endothelial function score 7.9 (1.3) +1.9 (0.6) .001 6.1 (1.1) +0.2 (0.2) .09 +1.7 (1.0 to 2.4) .001
hs-CRP and cytokines, median (IQR)
hs-CRP, mg/L 1.7 (0.4-4.9) −1.1 (0.4) .01 2.8 (0.5-5.5) −0.1 (0.3) .12 −1 (−1.7 to −0.3) .01
IL-6, pg/mL 1.4 (0.4-3.8) −0.7 (0.3) .02 1.8 (0.5-4.5) −0.1 (0.2) .21 −0.6 (−1.1 to −0.1) .04
IL-7, pg/mL 1.9 (0.5-5.2) −0.5 (0.2) .04 2.6 (0.7-6.0) 0 (0.1) .78 −0.5 (−0.9 to −0.1) .04
IL-18, pg/mL 148 (92-219) −19 (9) .03 171 (100-230) −4 (3) .08 −15 (−28 to −2) .03
No. of components of the
metabolic syndrome, No. (%)
Adjusted for weight changes
3 31 (34) −43 59 (66) −17 −26
4 10 (11) −8 12 (13) −4 −4 .001
5 1 (1) −7 7 (8) −1 −6
Unadjusted for weight changes
3 24 (27) −50 55 (61) −21 −29
4 6 (7) −12 11 (12) −5 −7 .001
5 0 −8 6 (7) −2 −6
Abbreviations: HDL-C, high-density lipoprotein cholesterol; HOMA, homeostatic model assessment; hs-CRP, high-sensitivity C-reactive protein; IL, interleukin; IQR, interquartile
range.
SI conversion factors: To convert glucose to mmol/L, multiply values by 0.0555; to convert insulin to pmol/L, multiply values by 7.715; to convert total cholesterol and HDL-C to
mmol/L, multiply values by 0.0259; to convert triglycerides to mmol/L, multiply values by 0.0113.
*Calculated as weight in kilograms divided by the square of height in meters.
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thirds. In a population-based study
involving 22043 apparently healthy
adults in Greece, adherence to a tradi-
tional Mediterranean diet was associ-
ated with significantly lower total mor-
tality, mortality from coronary heart
disease, and mortality from cancer.36
Despite a robust inverse association
between the overall Mediterranean-diet
scoreandmortality,noappreciable asso-
ciations were seen for most of the indi-
vidualdietarycomponents,whichwould
suggest that the cumulative effects (syn-
ergisticor interactive)ofmultipledietary
componentsmaybesubstantial. Inother
words, theeffect appears tobemore than
the sum of its parts.
The results of this study represent the
first demonstration, to our knowledge,
that a Mediterranean-style diet rich in
whole grains, fruits, vegetables, le-
gumes, walnuts, and olive oil might be
effective in reducing both the preva-
lence of the metabolic syndrome and its
associated cardiovascular risk. One of the
mechanisms responsible for the cardio-
protective effect of such a diet may be
through reduction of the low-grade in-
flammatory state associated with the
metabolic syndrome. Although weight
reduction remains a cornerstone of
therapy for the metabolic syndrome,
from a public health perspective adop-
tion of a diet similar to that investi-
gated herein may provide further ben-
efit on cardiovascular risk, especially in
patients who do not lose weight.
Author Affiliations: Chair and Division of Metabolic
Diseases (Drs Esposito, Marfella, Ciotola, Di Palo, and
D. Giugliano), Chair of Urology (Drs F. Giugliano and
D’Armiento), and Chair of Plastic and Reconstructive
Surgery (Drs G. Giugliano and D’Andrea), Second Uni-
versity of Naples, Naples, Italy.
Author Contributions: Dr D. Giugliano had full ac-
cess to all of the data in the study and takes respon-
sibility for the integrity of the data and the accuracy
of the data analyses.
Study concept and design; drafting of the manu-
script: Esposito, D. Giugliano.
Acquisition of data: Esposito, Marfella, Ciotola, Di Palo,
F. Giugliano, G. Giugliano.
Analysis and interpretation of data: Esposito,
D’Armiento, D’Andrea, D. Giugliano.
Critical revision of the manuscript for important in-
tellectual content: Esposito, Marfella, Ciotola, Di Palo,
F. Giugliano, G. Giugliano, D’Armiento, D’Andrea, D.
Giugliano.
Statistical analysis: Marfella, D. Giugliano.
Obtained funding: D. Giugliano.
Administrative, technical, ormaterial support:Ciotola,
Di Palo, F. Giugliano, G. Giugliano, D’Andrea.
Study supervision: Esposito, D’Armiento, D. Giugliano.
Funding/Support: This study was funded by the Sec-
ond University of Naples.
Role of the Sponsor: The Second University of Naples
had no role in the conduct of the study; in the collec-
tion, analysis, or interpretation of data; in the prepa-
ration of the data; or in the preparation, review, or
approval of the manuscript.
REFERENCES
1. Ford ES, Giles WH, Dietz WH. Prevalence of the
metabolic syndrome among US adults: findings from
the Third National Health and Nutrition Examination
Survey. JAMA. 2002;287:356-359.
2. Executive Summary of the Third Report of the Na-
tional Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel
III). JAMA. 2001;285:2486-2497.
3. Groop L. Genetics of the metabolic syndrome. Br
J Nutr. 2000;83(suppl 1):S39-S48.
4. Lidfeldt J, Nyberg P, Nerbrand C, et al. Socio-
demographic and psychological factors are associ-
ated with features of the metabolic syndrome: the
Women’s Health in the Lund Area (WHILA) study.Dia-
betes Obes Metab. 2003;5:106-112.
5. Han TS, Sattar N, Williams K, et al. Prospective study
of C-reactive protein in relation to the development of
diabetes and metabolic syndrome in the Mexico City
Diabetes Study. Diabetes Care. 2002;25:2016-2021.
6. Esposito K, Pontillo A, Giugliano F, et al. Associa-
tion of low interleukin-10 levels with the metabolic
syndrome in obese women. J Clin Endocrinol Metab.
2003;88:1055-1058.
7. Tamakoshi K, Yatsuya H, Kondo T, et al. The meta-
bolic syndrome is associated with elevated circulat-
ing C-reactive protein in healthy reference range, a
systemic low-grade inflammatory state. Int JObesRelat
Metab Disord. 2003;27:443-449.
8. Ridker PM, Buring JE, Cook NR, et al. C-reactive
protein, the metabolic syndrome, and risk of incident
cardiovascular events: an 8-year follow-up of 14719
initially healthy American women. Circulation. 2003;
107:391-397.
9. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive
protein in healthy subjects: associations with obesity, in-
sulin resistance, and endothelial dysfunction: a poten-
tial role for cytokines originating from adipose tissue?
Arterioscler Thromb Vasc Biol. 1999;19:972-978.
10. Ziccardi P, Nappo F, Giugliano G, et al. Reduc-
tion of inflammatory cytokine concentrations and im-
provement of endothelial functions in obese women
after weight loss over one year. Circulation. 2002;
105:804-809.
11. Wirfalt E, Hedblad B, Gullberg B, et al. Food pat-
terns and components of the metabolic syndrome in
men and women: a cross-sectional study within the
Malmo Diet and Cancer cohort.Am J Epidemiol. 2001;
154:1150-1159.
12. Mennen L, Lafay L, Feskens EJ, et al. Possible pro-
tective role of bread and dairy products on the risk of
the metabolic syndrome. Nutr Res. 2000;20:335-347.
13. McKeown NM, Meigs JB, Liu S, et al. Carbohy-
drate nutrition, insulin resistance, and the prevalence
of the metabolic syndrome in the Framingham off-
spring cohort. Diabetes Care. 2004;27:538-546.
14. Krauss RM, Eckel RH, Howard B, et al. AHA Di-
etary Guidelines: revision 2000: a statement for health-
care professionals from the Nutrition Committee of
the American Heart Association. Circulation. 2000;
102:2284-2299.
15. Robertson RM, Smaha L. Can a Mediterranean-
style diet reduce heart disease? Circulation. 2001;
103:1821-1822.
16. Harris TB, Ferrucci L, Tracy RP, et al. Association
of elevated interleukin-6 and C-reactive protein lev-
els with mortality in the elderly.Am JMed. 1999;106:
506-512.
17. BlankenbergS,Tiret L,BickelC, et al. Interleukin-18
isa strongpredictorof cardiovasculardeath in stableand
unstable angina. Circulation. 2002;106:24-30.
18. Damaˆs JK, Væhre T, Yndestad A, et al. Interleukin-
7-mediated inflammation in unstable angina: pos-
sible role of chemokines and platelets. Circulation.
2003;107:2670-2676.
19. Giugliano D, Marfella R, Verrazzo G, et al.
l-Arginine for testing endothelium-dependent vascu-
lar functions in humans. Am J Physiol. 1997;273:
E606-E612.
20. Esposito K, Nappo F, Giugliano F, et al. Effect of
dietary antioxidants on post-prandial endothelial dys-
function induced by a high-fat meal in healthy sub-
jects. Am J Clin Nutr. 2003;77:139-143.
21. Matthews DR, Hosker JP, Rudenski AS, et al. Ho-
meostasis model assessment: insulin resistance and
-cell function from fasting plasma glucose and in-
sulin concentrations in man. Diabetologia. 1985;28:
412-419.
22. Grundy SM, Hansen B, Smith SC, et al. Clinical
management of the metabolic syndrome. Circula-
tion. 2004;109:551-556.
23. Bastard JP, Jardel C, Bruckert E, et al. Elevated lev-
els of interleukin 6 are reduced in serum and subcu-
taneous adipose tissue of obese women after weight
loss. J Clin Endocrinol Metab. 2000;85:3338-3342.
24. Dandona P, Aljada A, Mohanty P. The anti-
inflammatory and potential anti-atherogenic effect of
insulin: a new paradigm. Diabetologia. 2002;45:924-
930.
25. Plotnick GD, Corretti MC, Vogel RA. Effect of an-
tioxidant vitamins on the transient impairment of en-
dothelium-dependent brachial artery vasoactivity fol-
lowing a single high-fat meal. JAMA. 1997;278:1682-
1686.
26. Nappo F, Esposito K, Cioffi M, et al. Postprandial
endothelial activation in healthy subjects and type 2
diabetic patients: role of fat and carbohydrate meals.
J Am Coll Cardiol. 2002;39:1145-1150.
27. Esposito K, Nappo F, Giugliano F, et al. Meal
modulation of circulating interleukin 18 and adipo-
nectin concentrations in healthy subjects and in pa-
tients with type 2 diabetes mellitus. Am J Clin Nutr.
2003;78:1135-1140.
28. Andoh A, Bamba T, Sakasi M. Physiological and
anti-inflammatory roles of dietary fiber and butyrate
in intestinal functions. JPEN J Parenter Enteral Nutr.
1999;23(suppl):S70-S73.
29. Kris-Etherton PM, Harris WS, Appel LJ, Ameri-
can Heart Association Nutrition Committee. Fish con-
sumption, fish oil, omega-3 fatty acids, and cardio-
vascular disease. Circulation. 2002;106:2747-2757.
30. Pasceri V, Willerson JT, Yeh ET. Direct proinflam-
matory effect of C-reactive protein on human endo-
thelial cells. Circulation. 2000;102:2165-2168.
31. Yeh ET, Anderson HV, Pasceri V, et al. C-reactive
protein: linking inflammation to cardiovascular compli-
cations. Circulation. 2001;104:974-975.
32. Ferna´ndez-Real JM, Ricart W. Insulin resistance
and chronic cardiovascular inflammatory syndrome.
Endocr Rev. 2003;24:278-301.
33. Hu FB, Willett WC. Optimal diets for prevention of
cardiovascular disease. JAMA. 2002;288:2569-2578.
34. de Lorgeril M, Salen P, Martin JL, et al. Mediter-
ranean diet, traditional risk factors, and the risk of car-
diovascular complications after myocardial infarc-
tion: final report of the Lyon Heart Study.Circulation.
1999;99:779-785.
35. Singh RB, Dubnow G, Niaz MA, et al. Effect of
an Indo-Mediterranean diet on progression of coro-
nary heart disease in high risk patients (Indo-
Mediterranean Diet Heart Study): a randomized single-
blind trial. Lancet. 2002;360:1455-1461.
36. Trichopoulou A, Costacou T, Bamia C, Tricho-
poulos D. Adherence to a Mediterranean diet and sur-
vival in a Greek population. N Engl J Med. 2003;348:
2599-2608.
MEDITERRANEAN DIET AND THE METABOLIC SYNDROME
1446 JAMA, September 22/29, 2004—Vol 292, No. 12 (Reprinted) ©2004 American Medical Association. All rights reserved.
 at Seconda Universita Studi Napol on 10 December 2010jama.ama-assn.orgDownloaded from 
